medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2020, Number 1

<< Back Next >>

Alerg Asma Inmunol Pediatr 2020; 29 (1)

Participants in the immunological response to SARS-CoV-2 infection

López PGT, Ramírez SMLP, Torres AMS

Language: Spanish
References: 44
Page: 5-15
PDF size: 401.43 Kb.


ABSTRACT

A compilation of what is reported in the literature on the immune response in SARS-CoV-2 infection is presented. The elements of the non-specific immune response, that triggered by T lymphocytes and that mediated by antibodies, are analyzed. The risk factors most frequently involved with poor evolution are listed and finally the therapeutic possibilities are briefly described.


REFERENCES

  1. Abbas AK, Lichtman AH, Pillai S. In: Inmunología celular y molecular. Capítulo 1, 8ta ed. Elsevier, 2015, pp. 9-20.

  2. Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ et al. The origin, transmission and clinical therapies on coronavirus disease 2019(COVID-19) outbreak-an update on the Status. Mil Med Res. 2020; 7: 11. https://doi.org/10.1186/s40779-020-00240-0.

  3. Letko M, Marzi A, Munster V. Functional assessmentof cell entry and receptor usage for SARS-CoV-2 andother lineage B betacoronaviruses. Nat Microbiol. 2020; 5: 562-569. doi: 10.1038/s41564-020-0688-y.

  4. Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018; 14 (8): e1007236.

  5. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59: 118-128.

  6. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290: 374-380.

  7. Organización Mundial de la Salud: índice de letalidad de casos de SRAS, periodo de incubación en la URL de la World. Wide Web: http://www.who.int/csr/sarsarchive/2003_05_07a/en/.

  8. Cervantes B, Kalinke U, Kizis Z, Lopez-Macias C, Thiel BV. Type I IFN-mediated protection of macrophages and dendritic cells secures control of murine coronavirus infection. J Immunol. 2009; 182: 1099-1106.

  9. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM et al. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol. 2007; 81: 8692-8706.

  10. Sims AC, Baric RS, Yount B, Burkett SE, Collins PL, Pickles RJ. Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol. 2005; 79: 155111-15524.

  11. Baas T, Taubenberger JK, Chong PY, Chui P, Katze MG. SARS-CoV virus-host interactions and comparative etiologies of acute respiratory distress syndrome as determined by transcriptional and cytokine profiling of formalin-fixed paraffin-embedded tissues. J Int Cyt Res. 2006; 26: 309-317.

  12. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007; 20 (4): 660-694.

  13. Sato K, Misawa N, Takeuchi JS, Kobayashi T, Izumi T, Aso H et al. Experimental adaptive evolution of simian immunodeficiency virus sivcpz to pandemic human immunodeficiency virus type 1 by using a humanized mouse model. J Virol. 2018; 92 (4): e01905-17.

  14. Cecere TE, Todd SM, Leroith T. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012; 4 (5): 833-846.

  15. Maloir Q, Ghysen K, von Frenckell C, Louis R, Guiot J. Acute respiratory distress revealing antisynthetase syndrome. Rev Med Liege. 2018; 73 (7-8): 370-375.

  16. Zhao J, Li K, Wohlford-Lenane C, Agnihothram SS, Fett C, Zhao J et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci USA. 2014; 111 (13): 4970-4975.

  17. Manni ML, Robinson KM, Alcorn JF. A tale of two cytokines: IL-17 and IL-22 in asthma and infection. Expert Rev Respir Med. 2014; 8 (1): 25-42.

  18. Ng OW, Chia A, Tan AT, Jadi RS, Leong HN, Bertoletti A et al. Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection. Vaccine. 2016; 34 (17): 2008-2014.

  19. Chen J, Lau YF, Lamirande EW, Paddock CD, Bartlett JH, Zaki SR et al. Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4+ T cells are important in control of SARS-CoV infection. J Virol. 2010; 84 (3): 1289-1301.

  20. Dutzan N, Abusleme L. T helper 17 cells as pathogenic drivers of periodontitis. Adv Exp Med Biol. 2019; 1197: 107-117.

  21. Yang Y, Xiong Z, Zhang S, Yan Y, Nguyen J, Ng B et al. Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J. 2005; 392 (Pt 1): 135-143.

  22. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clinical Infectious Diseases. ciaa344, https://doi.org/10.1093/cid/ciaa344.

  23. Xiao T, Gao Ch, Zhang S. Profile of specific antibodies to SARS-CoV-2: the first report. Journal of Infection. 2020. doi: https://doi.org/10.1016/j.jinf.2020.03.012.

  24. Ho MS, Chen WJ, Chen HY, Lin SF, Wang MC, Di J et al. Neutralizing antibody response and SARS severity. Emerg Infect Dis. 2005; 11: 1730-1737.

  25. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H et al. Caracterización genómica y epidemiología del nuevo coronavirus 2019: implicaciones para los orígenes del virus y la unión al receptor. Lancet. 2020; 20: 30251-30258. pii: S0140-6736.

  26. Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2. Int J Biol Sci. 2020; 16: 1718-1723.

  27. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020; 38: 10-18. doi: 10.12932/AP-200220-0773.

  28. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2010; 395: 1033-1034.

  29. McGonagle D, Sharifa K, O’Regand A, Bridgewooda C. Autoimmunity reviews, y registry CCT. A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19). 2020. https://doi.org/10.1016/j.autrev.2020.102537.

  30. Wu D, Yang XO. Respuestas TH17 en la tormenta de citoquinas de COVID-19: Un objetivo emergente del inhibidor de JAK2 Fedratinib. J Microbiol Immunol Infect. https://doi.org/10.1016/j.jmii.2020.03.005.

  31. Eakachai Prompetchara E, Ketloy E, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. doi. 10.12932/AP-200220-0772.

  32. (RITAC) Gauna M. https://fundacionio.com/wp-content/uploads/2020/04/Si%CC%81ndrome-RITAC.pdf.pdf.pdf.pdf.pdf.pdf.pdf.

  33. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv 2020; doi: 10.1101/2020.02.06.20020974.

  34. Harmer D, Gilbert M, Borman R, Clark KL. Quantitative mRNA expression procling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett. 2002; 532 (1-2): 107-110.

  35. Ling Lin, Lianfeng Lu, Wei Cao, Taisheng Li. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerging Microbes & Infections. 2020; 9: 727-732. doi: 10.1080/22221751.2020.1746199.

  36. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients With 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323 (11): 1061-1069.

  37. Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020. doi: 10.1101/2020.02.10.20021832.

  38. Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC et al. Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the National Institute for Public Health of the Netherlands. Radiology. https://doi.org/10.1148/radiol.2020201629.

  39. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18: 844-847. https://doi.org/10.1111/jth.14768.

  40. Pawelec G. Age and immunity: what is “immunosenescence”? Experimental Gerontology. 2018; 105: 4-9. doi: 10.1016/j.exger.2017.10.024.

  41. Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT et al. Insulin receptor-mediated stimulation boosts T cell immunity during inflammation and infection. Cell Metab. 2018; 28 (6): 922-934.e4. doi: 10.1016/j. cmet.2018.08.003.

  42. Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O’Toole T. Exposure to fine particulate air pollution is associated with endothelial injury and systemic inflammation. Circ Res. 2016; 119 (11): 1204-1214.

  43. Cai G. Bulk and single-cell transcriptomics identify tobacco-use disparity in lung gene expression of ACE2, the receptor of 2019-nCov. medRxiv. 2020; doi: 10.1101/2020.02.05.20020107 (preprint).

  44. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB Pharmacologic treatments for coro navirus disease 2019 (COVID-19) a review. JAMA. Publicado en línea el 13 de abril de 2020. doi: 10.1001 / jama.2020.6019.




2020     |     www.medigraphic.com